Infectious diseases now最新文献

{"title":"Buffalopox: An emerging zoonotic challenge","authors":"Amrita Pattanaik ,&nbsp;Lonika Lodha ,&nbsp;Srilatha Marate ,&nbsp;Dhanya K. ,&nbsp;B. Sushma Bhandarkar ,&nbsp;Sreelakshmi V. ,&nbsp;Nidhi Ashtaputre ,&nbsp;Reeta S. Mani","doi":"10.1016/j.idnow.2024.104954","DOIUrl":"10.1016/j.idnow.2024.104954","url":null,"abstract":"<div><p>As a variant of Vaccinia virus, Buffalopox virus is known to cause Buffalopox disease. In recent times, sporadic outbreaks of the infection in humans have been reported, especially in the endemic countries of Southeast Asia. Though mortality has not been high, associated morbidity is significant. Due to waning cross-protective immunity against smallpox, Buffalopox virus is one of the several orthopox viruses likely to emerge or reemerge. To combat this virus, early recognition, isolation, and management of the infection in animals and humans is of prime importance. In addition, vaccination in animals and humans at risk of acquiring infection is essential as a means of limiting animal-to-animal and animal-to-human spread of the virus. With this in mind, a collaborative approach between the animal and human health sectors is indispensable.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104954"},"PeriodicalIF":2.9,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001210/pdfft?md5=27feea7e9b30f5c36f69f8d2b98ea63f&pid=1-s2.0-S2666991924001210-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study","authors":"Derrick Lopez ,&nbsp;Douglas Pritchard ,&nbsp;Frank M. Sanfilippo ,&nbsp;Erin Kelty ,&nbsp;Amy Page ,&nbsp;Christopher Etherton-Beer ,&nbsp;Osvaldo P. Almeida ,&nbsp;David B. Preen","doi":"10.1016/j.idnow.2024.104953","DOIUrl":"10.1016/j.idnow.2024.104953","url":null,"abstract":"<div><h3>Objectives</h3><p>To compare the supply of molnupiravir and nirmatrelvir/ritonavir in relation to patient characteristics and other co-prescribed medicines and to estimate the number of patients without contraindications to nirmatrelvir/ritonavir who were treated with molnupiravir.</p></div><div><h3>Study design, setting</h3><p>Retrospective observational study of patients identified in the Pharmaceutical Benefits Scheme (PBS) 10 % sample dataset who were supplied with either molnupiravir or nirmatrelvir/ritonavir between May and December 2022. We supplemented the PBS dataset with aggregated counts from published literature to determine prevalence of clinical contraindications to nirmatrelvir/ritonavir.</p></div><div><h3>Main outcome measures</h3><p>We used multivariable Poisson regression to estimate risk ratios (RR) of receiving nirmatrelvir/ritonavir over molnupiravir.</p></div><div><h3>Results</h3><p>We identified 54,550 patients who received either nirmatrelvir/ritonavir (26.8 %) or molnupiravir (73.2 %). Their average age was 71.6 (SD = 13.4) years and 57.1 % were female. Patients were less likely to receive nirmatrelvir/ritonavir with increasing age (RR = 0.50; 95 % CI: 0.48–0.53; for ages 85 + compared to &lt; 65 years) or who had received medicines contraindicated for use with nirmatrelvir/ritonavir (RR = 0.66; 95 % CI: 0.64–0.68). During the study period, we estimated that between 28.4 % and 45.4 % of patients aged ≥ 65 years had received molnupiravir in the absence of pharmacological and clinical contraindications to nirmatrelvir/ritonavir.</p></div><div><h3>Conclusion</h3><p>Many prescriptions were written for molnupiravir where there were no contraindications to nirmatrelvir/ritonavir. The benefits that followed from prompt government action in approving and obtaining nirmatrelvir/ritonavir were therefore likely to be less than they could potentially have been. Governments should consider investing in quality improvement systems to ensure the best outcomes in terms of efficacy and safety.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104953"},"PeriodicalIF":2.9,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001209/pdfft?md5=01e404726ea452d9411fe60ff92f876a&pid=1-s2.0-S2666991924001209-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination of teenagers in France over a 10-year period (2012–2021)","authors":"","doi":"10.1016/j.idnow.2024.104952","DOIUrl":"10.1016/j.idnow.2024.104952","url":null,"abstract":"<div><h3>Objectives</h3><p>The objectives were to assess trends over the past 10 years in vaccination coverage rates (VCR) among adolescents in France aged 14–15 years, factors influencing decisions to vaccinate, and mothers’ opinions on adolescent vaccination.</p></div><div><h3>Patients and Methods</h3><p>The ‘Vaccinoscopie’ internet survey is completed each year by mothers of adolescents, with questions about vaccinations received by their children, and their attitudes and barriers to vaccination. The 2012 to 2021 surveys were analyzed in this study, including data from 1500 adolescents in 2012 and 1000 adolescents each year from 2013 to 2021.</p></div><div><h3>Results</h3><p>None of the adolescent VCR targets were met, despite significant increases since 2012 for vaccines with the lowest coverage rates and vaccines with high but insufficient coverage i.e., meningococcal C (28.7% to 60.8%), HPV in girls (14.2% to 40.8%), hepatitis B (31.6% to 47.3%) and pertussis (76.3% to 91.0%). Physicians remained the primary source of vaccination information for 90.4% of mothers, and their advice had a real impact on improving VCRs. Adolescents were increasingly involved (40.1%) in decisions about vaccination. Depending on the vaccine, over 80% of mothers currently consider adolescent vaccination as useful or essential. Since 2017, they also feel better informed.</p></div><div><h3>Conclusions</h3><p>Low and under-target VCRs put adolescents at risk of severe disease, and do not enable herd immunity or reduced transmission to other vulnerable age groups to be accomplished. Healthcare professionals must take every opportunity to check adolescents’ vaccination status and recommend catch-up vaccines where applicable. Vaccination in schools should be considered.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104952"},"PeriodicalIF":2.9,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001192/pdfft?md5=d7fb42880d60a750273b2993e01ae4d4&pid=1-s2.0-S2666991924001192-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor necrosis factor-alpha antagonists in patients with complicated spinal tuberculosis: A case series and literature review","authors":"Aayesha J. Soni ,&nbsp;Yashvir Rugbeer ,&nbsp;Julius Rozmiarek ,&nbsp;Abi Manesh ,&nbsp;Suzaan Marais","doi":"10.1016/j.idnow.2024.104941","DOIUrl":"10.1016/j.idnow.2024.104941","url":null,"abstract":"<div><h3>Introduction</h3><p>Spinal tuberculosis is often associated with poor outcomes; host-directed inflammation involving the spine contributes to this disability.</p></div><div><h3>Methods</h3><p>A retrospective review of patients with complicated spinal tuberculosis having received tumor necrosis factor-alpha (TNF-α) antagonists at a referral hospital in South Africa. A literature review was performed to identify all published cases of complicated spinal tuberculosis that received a TNF-α antagonist as part of their treatment.</p></div><div><h3>Results</h3><p>We describe 23 cases, of which 19 were previously reported in the literature. All patients were treated with either thalidomide (n<!--> <!-->=<!--> <!-->6) or infliximab (n<!--> <!-->=<!--> <!-->16), except for one who received both. All in all, 21 (91%) cases improved neurologically and, at the end of follow-up, 18 could walk.</p></div><div><h3>Conclusion</h3><p>There is accumulating experience to confer the efficacy and safety of TNF-α antagonists in treating complicated spinal tuberculosis cases. Evidence from randomized controlled trials is urgently required to substantiate these findings.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104941"},"PeriodicalIF":2.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001088/pdfft?md5=1c1b2b3269708c2f4f5882c94dd65920&pid=1-s2.0-S2666991924001088-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual health insurance data of antibiotic delivery in previous months as a tool to predict bacterial resistance of urinary tract infection: A prospective cohort study","authors":"Kévin Alexandre ,&nbsp;André Gillibert ,&nbsp;Sandrine Dahyot ,&nbsp;Roland Fabre ,&nbsp;Francis Kuhn ,&nbsp;Jacques Benichou ,&nbsp;Valérie Delbos ,&nbsp;François Caron","doi":"10.1016/j.idnow.2024.104942","DOIUrl":"10.1016/j.idnow.2024.104942","url":null,"abstract":"<div><h3>Objectives</h3><p>We aimed to quantify the individual risk of antimicrobial resistance among patients with community-acquired <em>Escherichia coli</em> urinary tract infection (UTI) according to their antibiotic exposure over the previous 18 months.</p></div><div><h3>Patients and methods</h3><p>French patients were prospectively recruited in two centers in 2015–2017. Resistance of isolates to amoxicillin (AMX), amoxicillin-clavulanate (AMC), third-generation cephalosporins (3GC), trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolones (FQ) and fosfomycin (FOS) was analysed according to previous intra-class and inter-class antibiotic exposure documented in health insurance files.</p></div><div><h3>Results</h3><p>Previous antibiotic exposure was found in 588 (81.4 %) of the 722 UTI cases analysed (564 patients). Recent exposure (three months before UTI) was associated with stronger intra-class impact on <em>E. coli</em> resistance compared to remote exposure (18 months before UTI) for AMX, AMC, FQ and TMP-SMX, with respective adjusted odds ratios [95 % confidence interval] of 1.63 [1.20–2.21], 1.59 [1.02–2.48], 3.01 [1.90–4.77], and 2.60 [1.75–3.87]. AMX, FQ, and TMP-SMX also showed significant inter-class impact. Resistance to 3GC was not significantly associated with intraclass exposure (adjusted OR: 0.88 [0.41–1.90]). FOS resistance was remarkably low (0.4 %). Duration of the antibiotic-free period required for resistance risk to drop below 10 %, the threshold for empirical use in UTI, was modelled as &lt; 1 month for 3GC, &gt;18 months for AMX and TMP-SMX and uncertain for AMC (5.2 months [2.3 to &gt; 18]) and FQ (17.4 months [7.4 to &gt; 18]).</p></div><div><h3>Conclusions</h3><p>Resistance of <em>E. coli</em> causing UTI is partially predicted by previous personal antibiotic delivery.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104942"},"PeriodicalIF":2.9,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266699192400109X/pdfft?md5=7f0af847a90528bec7c4dd88b0005f87&pid=1-s2.0-S266699192400109X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contributions of the qualitative Qualicor study embedded in a cohort study on the circumstances of SARS-CoV 2 infection in France","authors":"","doi":"10.1016/j.idnow.2024.104943","DOIUrl":"10.1016/j.idnow.2024.104943","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aims to understand a major result of ComCor, an online epidemiological study conducted to identify the circumstances of COVID-19 infection in France from 2020 to 2022: One third of respondents reported ignoring the circumstances of their infection.</p></div><div><h3>Methods</h3><p>We conducted a qualitative study through semi-structured interviews, diagnosed in spring or summer 2021. Interviews were audio recorded, transcribed, and thematically analyzed.</p></div><div><h3>Results</h3><p>Fifty interviews were conducted. Half of the participants in Qualicor were able to identify several at-risk situations, most often involving their entourage (family, friends, colleagues), but were uncertain as to which specific situation was the source of infection. Less than one quarter strongly suspected a specific situation without certainty, a similar proportion were unable to identify any circumstances, and only two people were certain about the origin of the infection. Several factors contributed to this lack of knowledge: a desire to conceal these circumstances (in a few rare cases), limitations of the questionnaire, lack of knowledge about how the virus is transmitted, selective perception of at-risk situations, co-existence of several possible sources of infection, and the difficulty of taking an objective view of certain circumstances of transmission.</p></div><div><h3>Conclusion</h3><p>Our study shows the benefits of a mixed approach designed to better understand the perception of Covid 19 contamination circumstances in the French population. It also highlights the need to strengthen or improve communication on modes of virus transmission, especially airborne transmission, and the importance of maintaining certain preventive behaviors after vaccination.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104943"},"PeriodicalIF":2.9,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001106/pdfft?md5=6e16cd2dbc614591adf28487063fcde6&pid=1-s2.0-S2666991924001106-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enterococcus-related vascular graft infection: A case series","authors":"Jules Bauer ,&nbsp;Olivier Robineau ,&nbsp;Jonathan Sobocinski ,&nbsp;Piervito D’Elia ,&nbsp;Anne Boucher ,&nbsp;Barthelemy Lafon-Desmurs ,&nbsp;Macha Tetart ,&nbsp;Agnes Meybeck ,&nbsp;Pierre Patoz ,&nbsp;Eric Senneville","doi":"10.1016/j.idnow.2024.104940","DOIUrl":"10.1016/j.idnow.2024.104940","url":null,"abstract":"<div><h3>Objectives</h3><p>We aimed to assess the frequency, management, and burden of enterococcal-related vascular graft infection.</p></div><div><h3>Patients and methods</h3><p>From 2008 to 2021, data regarding all episodes of vascular graft infections initially managed or secondarily referred to our referral center were prospectively collected. We described the history and management of the infection, depending on the type of prosthesis used.</p></div><div><h3>Results</h3><p>The frequency of enterococcal-related vascular graft infections was 29/249 (12 %). Most of them were early infections (22/29, 76 %). Infections were polymicrobial (26/29, 90 %), mostly associated with Enterobacterales. Among patients with positive blood cultures, 7/8 (88 %) involved enterococci. Patients with enterococcal-related vascular graft infections were mainly (22/29, 76 %) treated with an association of antibiotics. Mortality and relapse occurred in 28 % and 7 % respectively of the cases.</p></div><div><h3>Conclusions</h3><p>Enterococcal-related vascular graft infections occurred in patients with comorbidities, during the early period following surgery and were more frequent in cases of intra-cavitary prosthesis. Their potential virulence needs to be considered, especially in polymicrobial infections.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 6","pages":"Article 104940"},"PeriodicalIF":2.9,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001076/pdfft?md5=e55fb82e995d31ab20b7d44dd8437454&pid=1-s2.0-S2666991924001076-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune debt: A concept conducive to improved public health awareness","authors":"Hai-Feng Liu,&nbsp;Hong-Min Fu","doi":"10.1016/j.idnow.2024.104939","DOIUrl":"10.1016/j.idnow.2024.104939","url":null,"abstract":"","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104939"},"PeriodicalIF":2.9,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001064/pdfft?md5=8a99a87e0a218f6b2360b71f03a11b9d&pid=1-s2.0-S2666991924001064-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis of Chikungunya virus in neurological disorders","authors":"Vivaldo G. da Costa ,&nbsp;Marielena V. Saivish ,&nbsp;Paola F. Sinhorini ,&nbsp;Maurício L. Nogueira ,&nbsp;Paula Rahal","doi":"10.1016/j.idnow.2024.104938","DOIUrl":"10.1016/j.idnow.2024.104938","url":null,"abstract":"<div><p>Chikungunya disease typically presents with the fever-arthralgia-rash symptom triad. However, an increase in the number of atypical clinical manifestations, particularly neurological disorders, has occurred. The current evidence regarding the pooled prevalence of Chikungunya virus (CHIKV)-associated neurological cases (CANCs) suspected of having an arboviral aetiology is not well-understood. Therefore, this <em>meta</em>-analysis included 19 studies (n = 7319 patients) and aimed to determine the pooled rate of exposure to CANC. The pooled positivity rate of CANC was 12 % (95 % CI: 6–19), and Brazil was overrepresented (11/19). These estimations varied between 3 and 14 % based on the diagnostic method (real-time PCR vs. ELISA-IgM) and biological samples (cerebrospinal fluid or blood specimens) used for detection of CHIKV. Regarding the frequency of CHIKV in neurological clinical subgroups, the rates were higher among patients with myelitis (27 %), acute disseminated encephalomyelitis (27 %), Guillain–Barré syndrome (15 %), encephalitis (12 %), and meningoencephalitis (7 %). Our analysis highlights the significant burden of CANC. However, the data must be interpreted with caution due to the heterogeneity of the results, which may be related to the location of the studies covering endemic periods and/or outbreaks of CHIKV. Current surveillance resources should also focus on better characterizing the epidemiology of CHIKV infection in neurological disorders. Additionally, future studies should investigate the interactions between CHIKV and neurological diseases with the aim of gaining deeper insight into the mechanisms underlying the cause-and-effect relationship between these two phenomena.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104938"},"PeriodicalIF":2.9,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001052/pdfft?md5=2085a4680d3754d325288e13eea9515b&pid=1-s2.0-S2666991924001052-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141394036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The latest news in France before distribution of third-generation pneumococcal conjugate vaccines","authors":"Robert Cohen ,&nbsp;Corinne Levy ,&nbsp;Emmanuelle Varon","doi":"10.1016/j.idnow.2024.104937","DOIUrl":"10.1016/j.idnow.2024.104937","url":null,"abstract":"<div><h3>Introduction</h3><p>In 2023 in France, 15 valent- pneumococcal conjugate vaccines (PCV15) have been recommended as alternatives to PCV13 for children &lt; 2 years. PCV20 has been recommended for at-risk adults but not yet for infants, while PCV21 targets older adults. We endeavored to estimate the potential benefit of new pneumococcal vaccines in preventing invasive pneumococcal infections by comparing serotype extension to PCV13.</p></div><div><h3>Patients and methods</h3><p>The National Reference Centre for Pneumococci distributed <em>S. pneumoniae</em> IPD serotypes from children and adults.</p></div><div><h3>Results</h3><p>In 2022, for children under 24 months, PCV15 and PCV20 ensured 10 % and 36 % more coverage against IPD than PCV13. For adults, PCV15, PCV20, and PCV21 covered up to 3 %, 26 %, and 50 % more IPD cases than PCV13.</p></div><div><h3>Conclusion</h3><p>The new generation of pneumococcal vaccines could reduce the burden of invasive pneumococcal infections through serotype extension. Additional studies are needed in parallel to optimize their utilization and improve vaccine coverage in France.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 5","pages":"Article 104937"},"PeriodicalIF":3.5,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991924001040/pdfft?md5=d3292318b7a1e75f184fa58a2870394d&pid=1-s2.0-S2666991924001040-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}